Latest news

• France wants Avastin used in place of Lucentis

  taking the lead from an earlier antitrust investigation in the country that resulted in the levying of a 182.5m fine.

• Lundbeck still 'appalled' by EC's €94m anti-competition fine

  An EC investigation concluded in June the Danish pharma company had collaborated with several other companies to delay the entry of generic competition for its big-selling antidepressant Celexa/ Cipramil (citalopram).

• Novartis, Roche under scrutiny in Italy on Avastin/Lucentis collusion claims

  Antitrust authorities in Italy open investigation into the pharma companies. Antitrust authorities in Italy have opened an investigation into claims Novartis and Roche colluded to restrict the availability of a

• EC to investigate Novartis and J&J in antitrust probe

  Claims companies agreed to delay entry of generic painkiller. Johnson &Johnson and Novartis are the latest pharma companies to face a European Commission investigation into anticompetitive practices, this time for allegedly ... The 'statement of

• EC investigates J&J/Novartis over fentanyl

  The European Commission has launched an antitrust investigation to assess if Johnson &Johnson and Novartis' generics division, Sandoz, hindered entry of generic versions of pain drug fentanyl into the Netherlands. ... The European Commission (EC) has